Track CRDF and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Create a free account to build watchlists, compare peers, and value any stock.
No credit card required
CRDF - Cardiff Oncology Inc (CRDF) has a revenue of $593.00K, down 13.3% over the past year and up 10.1% per year over the past five years.
Revenue TTM
$593.00K
5Y CAGR
10.13%
3Y CAGR
15.39%
Gross Margin
-1890.39%
| Year | Revenue | Change |
|---|---|---|
| 2025 | $593.00K | -13.30% |
| 2024 | $684.00K | +40.16% |
| 2023 | $488.00K | +26.42% |
| 2022 | $386.00K | +7.52% |
| 2021 | $359.00K | -1.98% |
| 2020 | $366.25K | -17.56% |
| 2019 | $444.26K | +17.43% |
| 2018 | $378.31K | -25.14% |
| 2017 | $505.38K | +32.65% |
| 2016 | $381.00K | - |
| Quarter | Revenue | Change |
|---|---|---|
| Q4 2025 | $243.00K | +102.50% |
| Q3 2025 | $120.00K | -0.83% |
| Q2 2025 | $121.00K | +11.01% |
| Q1 2025 | $109.00K | -27.81% |
| Q4 2024 | $151.00K | -8.48% |
| Q3 2024 | $165.00K | +1.23% |
| Q2 2024 | $163.00K | -20.49% |
| Q1 2024 | $205.00K | +31.41% |
| Q4 2023 | $156.00K | +10.64% |
| Q3 2023 | $141.00K | +30.56% |
| Q2 2023 | $108.00K | +30.12% |
| Q1 2023 | $83.00K | -35.16% |
| Q4 2022 | $128.00K | +37.63% |
| Q3 2022 | $93.00K | +2.20% |
| Q2 2022 | $91.00K | +22.97% |
| Q1 2022 | $74.00K | -44.36% |
| Q4 2021 | $133.00K | +54.65% |
| Q3 2021 | $86.00K | +26.47% |
| Q2 2021 | $68.00K | -5.56% |
| Q1 2021 | $72.00K | -39.63% |
| Q4 2020 | $119.25K | -12.31% |
| Q3 2020 | $136.00K | +216.28% |
| Q2 2020 | $43.00K | -36.76% |
| Q1 2020 | $68.00K | -26.55% |
| Q4 2019 | $92.58K | +79.11% |
| Q3 2019 | $51.69K | -62.55% |
| Q2 2019 | $138.00K | -14.81% |
| Q1 2019 | $162.00K | +107.69% |
| Q4 2018 | $78.00K | -11.73% |
| Q3 2018 | $88.36K | -20.97% |
| Q2 2018 | $111.81K | +11.66% |
| Q1 2018 | $100.14K | -45.87% |
| Q4 2017 | $185.00K | +50.01% |
| Q3 2017 | $123.33K | +20.90% |
| Q2 2017 | $102.01K | +7.34% |
| Q1 2017 | $95.04K | +39.76% |
| Q4 2016 | $68.00K | -23.69% |
| Q3 2016 | $89.11K | -13.82% |
| Q2 2016 | $103.40K | -14.18% |
| Q1 2016 | $120.49K | - |
Revenue — often called the top line — is the total amount a company earns from selling its products and services before any expenses are deducted. Consistent revenue growth is a core signal of expanding demand and a healthy business.